We also investigated whether the deletion or inhibition of DDX5 was effective in Ba/F3 cells transformed with the BCR-ABL T315I mutant, which is resistant to BCR-ABL inhibitors, and verified the potential of CML treatment targeting DDX5. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.